Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States Revenue	851.33M	697.16M	526.52M
United States Revenue Growth	22.11%	32.41%	25.18%
International Revenue	51.24M	41.85M	37.42M
International Revenue Growth	22.43%	11.84%	29.40%
Revenue (Total)	902.57M	739.02M	563.95M
Revenue (Total) Growth	22.13%	31.04%	25.45%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Precision Oncology Testing Revenue	-	687.94M	514.25M
Precision Oncology Testing Revenue Growth	-	33.77%	31.17%
Development Services and Other Revenue	-	51.08M	49.70M
Development Services and Other Revenue Growth	-	2.78%	-13.55%
Revenue (Total)	902.57M	739.02M	563.95M
Revenue (Total) Growth	22.13%	31.04%	25.45%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Precision Oncology Testing Gross Profit	-	427.36M	308.72M
Precision Oncology Testing Gross Profit Growth	-	38.43%	26.60%
Development Services and Other Gross Profit	-	21.86M	28.18M
Development Services and Other Gross Profit Growth	-	-22.41%	-42.92%
Gross Profit (Total)	902.57M	449.22M	336.90M
Gross Profit (Total) Growth	100.92%	33.34%	14.90%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Clinical Test Sales Volume	254.30K	206.70K	172.90K
Clinical Test Sales Volume Growth	23.03%	19.55%	38.54%
Biopharmaceutical Test Sales Volume	-	40.50K	29.90K
Biopharmaceutical Test Sales Volume Growth	-	35.45%	15.00%

Updated Oct 29, 2025. Data Source: Fiscal.ai.